

Global Non-Proliferative Diabetic Retinopathy Market - 2023-2031

<https://marketpublishers.com/r/G4F7A0EC6B24EN.html>

Date: August 2025

Pages: 219

Price: US\$ 2,999.00 (Single User License)

ID: G4F7A0EC6B24EN

Abstracts

The Global Non-Proliferative Diabetic Retinopathy Market was valued at US\$ 2.68 billion in 2023 and is anticipated to reach US\$ 4.71 billion by 2031, at a CAGR of 0.073 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Non-Proliferative Diabetic Retinopathy Market.

This report delivers a comprehensive overview of the Global Non-Proliferative Diabetic Retinopathy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Non-Proliferative Diabetic Retinopathy Market. The Global Non-Proliferative Diabetic Retinopathy Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

Global Non-Proliferative Diabetic Retinopathy Market Scope:

By Type

Mild NPDR

Moderate NPDR

Severe NPDR

By Treatment

Anti-Vascular Endothelial Growth Factor (VFGF) Medication

Intraocular Steroid Injection (Triamcinolone Acetonide (TA))

Steroid Implants

Vitrectomy

By End-User

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Key Players

Bayer AG

Regeneron Pharmaceuticals Inc.

Biocon

F. Hoffmann-La Roche

AbbVie Inc

Novartis AG

Oxurion NV

Ampio Pharmaceuticals, Inc.

Glycadia Pharmaceuticals

Ocuphire Pharma, Inc.

Major Highlights

This report delivers a comprehensive overview of the Global Non-Proliferative Diabetic Retinopathy Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Non-Proliferative Diabetic Retinopathy Market. The Global Non-Proliferative Diabetic Retinopathy Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East &

Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for

navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Type
- 3.2. Snippet by Treatment
- 3.3. Snippet by End-User
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Rising Prevalence of Diabetes and Diabetes-related Blindness
 - 4.1.1.2. XX
 - 4.1.2. Restraints
 - 4.1.2.1. Adverse Effects Associated with the Drugs
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis

6. BY TYPE

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 6.1.2. Market Attractiveness Index, By Type

6.2. Mild NPDR *

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Moderate NPDR

6.4. Severe NPDR

7. BY TREATMENT

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

7.1.2. Market Attractiveness Index, By Treatment

7.2. Anti-Vascular Endothelial Growth Factor (VEGF) Medication *

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.2.3. Avastin

7.2.4. Eylea

7.2.5. Lucentis

7.3. Intraocular Steroid Injection (Triamcinolone Acetonide (TA))

7.4. Steroid Implants

7.4.1. Dexamethasone Intravitreal Implant

7.4.2. Fluocinolone Acetonide Intravitreal Implant

7.4.3. Laser Surgery (Photocoagulation)

7.5. Vitrectomy

8. BY END-USER

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8.1.2. Market Attractiveness Index, By End-User

8.2. Hospital Pharmacies *

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Retail Pharmacies

8.4. Online Pharmacies

9. BY REGION

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

9.1.2. Market Attractiveness Index, By Region

9.2. North America

9.2.1. Introduction

9.2.2. Key Region-Specific Dynamics

9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.2.6.1. The U.S.

9.2.6.2. Canada

9.2.6.3. Mexico

9.3. Europe

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.3.6.1. Germany

9.3.6.2. U.K.

9.3.6.3. France

9.3.6.4. Spain

9.3.6.5. Italy

9.3.6.6. Rest of Europe

9.4. South America

9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.4.6.1. Brazil

9.4.6.2. Argentina

9.4.6.3. Rest of South America

9.5. Asia-Pacific

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.5.6.1. China

9.5.6.2. India

9.5.6.3. Japan

9.5.6.4. South Korea

9.5.6.5. Rest of Asia-Pacific

9.6. Middle East and Africa

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. COMPETITIVE LANDSCAPE

10.1. Competitive Scenario

10.2. Market Positioning/Share Analysis

10.3. Mergers and Acquisitions Analysis

11. COMPANY PROFILES

11.1. Bayer AG*

11.1.1. Company Overview

11.1.2. Product Portfolio and Description

11.1.3. Financial Overview

11.1.4. Key Developments

11.2. Regeneron Pharmaceuticals Inc.

11.3. Biocon

11.4. F. Hoffmann-La Roche

11.5. AbbVie Inc

11.6. Novartis AG

11.7. Oxurion NV

11.8. Ampio Pharmaceuticals, Inc.

11.9. Glycadia Pharmaceuticals

11.10. Ocuphire Pharma, Inc. (*LIST NOT EXHAUSTIVE)

12. APPENDIX

12.1. About Us and Services

12.2. Contact Us

I would like to order

Product name: Global Non-Proliferative Diabetic Retinopathy Market - 2023-2031

Product link: <https://marketpublishers.com/r/G4F7A0EC6B24EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4F7A0EC6B24EN.html>